Document is current
Any future updates will be listed below
-
Authors
Lugrin, Claire
Alecci, Lidia
Simillion, Cedric
Volkova-Volkmar, Ekaterina
Giboin, Louis-Solal
Kinsella, Fiona C.
McColgan, Peter
Wild, Edward J.
Dorn, Jonas
- License Information
-
More Information
Article History
Received: 1 October 2025
Accepted: 12 April 2026
First Online: 25 April 2026
Competing interests
: C. Lugrin is an employee of F. Hoffmann-La Roche Ltd. L. Alecci was an employee of F. Hoffmann-La Roche Ltd. C. Simillion is an employee of F.Hoffmann-La Roche Ltd. E. Volkova-Volkmar is an employee of F. Hoffmann-La Roche Ltd. P. McColgan is an employee of F. Hoffmann-La Roche Ltd. J. Dorn is an employee of F. Hoffmann-La Roche Ltd. L.-S. Giboin is a consultant for F.Hoffmann-La Roche Ltd via Efor Group. F. C. Kinsella is an employee of University College London. E. J. Wild reports grants from CHDI Foundation and European Huntington’s Disease Network. E. J. Wild reports consultancy/advisory board memberships with Alnylam, Annexon, Remix Therapeutics, Hoffman-La Roche Ltd, Ionis Pharmaceuticals, PTC Therapeutics, Skyhawk Therapeutics, Takeda, Teitur Trophics, Triplet Therapeutics, Uniqure, Wave Life Sciences, and Vico Therapeutics. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London.
